Lina Wang | Oncology | Best Researcher Award

Assoc Prof Dr.Lina Wang | Oncology | Best Researcher Award

Grant Funding:
  •  Dr. Wang has been the recipient of competitive research funding from the National Natural Science Foundation of China, which further underscores her research capabilities and the recognition of her work at the national level.
Assoc Prof Dr. Lina Wang, Affiliated Hospital of Jining Medical University, China

Profile

Scopus

OrcID

🏛️Early Academic Pursuits

  • Lina Wang completed her Bachelor’s degree at Taishan Medical University (2004-2010), followed by a Master’s degree from Peking Union Medical College (2010-2013). She further pursued her Ph.D. in Medicine at Shanghai Jiao Tong University School of Medicine (2013-2017). With an unrelenting drive for excellence, she completed a postdoctoral fellowship at the University of Maryland School of Medicine (2018-2020), where she deepened her understanding of oncological research and built a strong foundation for her future studies.

👨‍🔬 PROFESSIONAL ENDEAVORS

  • Since July 2017, Lina Wang has been serving as an Associate Professor at the Affiliated Hospital of Jining Medical University. Her professional journey has been marked by significant strides in cancer research, particularly focusing on lung cancer, esophageal cancer, and leukemia. She is committed to advancing cancer diagnosis, treatment, and prognosis through rigorous scientific investigation. Her postdoctoral research at the University of Maryland significantly enhanced her expertise in molecular oncology.

🏆 CONTRIBUTIONS AND RESEARCH FOCUS

  • Lina Wang’s research has brought significant advancements in the understanding of cancer pathogenesis, particularly in lung and esophageal cancers. Her work in developing efficient prognostic models based on cuproptosis and disulfidptosis has established her as a leader in the field of cancer biomarkers. She has extensively explored the molecular mechanisms underlying tumor progression and has validated several diagnostic and prognostic biomarkers for lung adenocarcinoma. Notably, her research on the TGF-β1/SH2B3 axis has provided new insights into the regulation of anoikis resistance and epithelial-mesenchymal transition (EMT) in lung cancer cells. Additionally, her earlier studies demonstrated that the deletion of Stk40 impairs definitive erythropoiesis in mouse fetal livers, contributing to the broader understanding of developmental biology.

📊 IMPACT AND INFLUENCE

  • Lina Wang’s groundbreaking research has not only advanced scientific knowledge but also holds potential to transform clinical practices in cancer diagnosis and treatment. By identifying tumor-associated diagnostic and prognostic markers, her work offers tangible benefits to clinical patients, improving the precision of medical interventions. Her research on the molecular mechanisms driving cancer progression contributes to the development of targeted therapies that can effectively treat aggressive cancers such as lung adenocarcinoma.

💰GRANTS AND FUNDING

  • Lina Wang’s research efforts have been recognized by the National Natural Science Foundation of China, which awarded her a grant (grant no. 81800182) for her project from 2019 to 2021. This funding has enabled her to push the boundaries of cancer research, supporting her work on diagnostic and prognostic markers, as well as molecular mechanisms in oncology.

🏅ACADEMIC CITES

  • Lina Wang’s publications on topics such as cuproptosis and cancer prognosis have been widely cited in scientific literature, reflecting the relevance and influence of her work in the academic community. Her research has contributed to the establishment of new prognostic models, and her findings have been cited in numerous oncology-focused journals, further solidifying her reputation as a key contributor in cancer research.

🚀LEGACY AND FUTURE CONTRIBUTIONS

  • As Lina Wang continues her academic journey, her future contributions promise to further enhance the understanding of cancer mechanisms and improve treatment strategies. With a focus on the identification of novel biomarkers and therapeutic targets, her work is expected to have a lasting impact on the fields of oncology and personalized medicine. Her ongoing research efforts are set to leave a lasting legacy in the medical community, inspiring future generations of researchers.

📄Publications

  •  Construction of lncRNA Prognostic Model Related to Disulfidptosis in Lung Adenocarcinoma
    Authors: Zhang, L., Wang, S., Wang, L.
    Journal: Heliyon, 2024, 10(15), e35657
  •  Prognostic Value and Immunological Function of Cuproptosis-Related Genes in Lung Adenocarcinoma
    Authors: Zhang, L., Wang, S., Wang, L.
    Journal: Heliyon, 2024, 10(9), e30446
  • LncRNA CALML3-AS1 Modulated by m6A Modification Induces BTNL9 Methylation to Drive Non-Small-Cell Lung Cancer Progression
    Authors: Zhang, H., Wang, S.-Q., Zhu, J.-B., Duan, C.-J., Zhang, C.-F.
    Journal: Cancer Gene Therapy, 2023, 30(12), pp. 1649–1662
  •  Research Progress on Ferroptosis in Lung Cancer 
    Authors: Dong, Z., Wang, L., Zhang, L., Hu, R.
    Journal: Journal of Chinese Physician, 2023, 25(11), pp. 1754–1757
  •  Alterations of Gut Microbiota and Gut Metabolites in the Young-Adult Vitiligo Patients
    Authors: Wu, Q., Cheng, P., Shao, T., Yao, S., Lu, B.
    Journal: Journal of the European Academy of Dermatology and Venereology, 2023, 37(7), pp. e904–e907

Ben Wang | Oncology | Best Researcher Award

Prof . Ben Wang | Oncology | Best Researcher Award

Recognition and Awards:
  •  Dr. Wang has received numerous awards throughout his career, including recognition from the National Science Foundation and various engineering societies. These accolades highlight his consistent contributions to advancing material science.
 Prof. Ben Wang , Zhejiang University , China

Profile

Scopus

OrcID

Google Scholar

🎓Early Academic Pursuits

  • Dr. Wang Ben was born in June 1983 in Qufu, China. His academic journey began with a Bachelor of Science in Chemical Engineering at Qufu Normal University in 2004. He then pursued his Master’s in Biology at Zhejiang University, focusing on the secondary metabolism of endophytic fungi from antitumor plants. His academic excellence earned him a Ph.D. in Chemistry & Biomedical Engineering from Zhejiang University in collaboration with Harvard University in 2011, under the guidance of Prof. Ruikang Tang and Prof. Ali Khademhosseini. His doctoral research focused on cellular shellization and surface engineering for single-cell modification and protection.

💼Professional Endeavors

  • Dr. Wang Ben’s career has been defined by his contributions to cancer metabolism and biomedical engineering. After completing his postdoctoral work at Zhejiang University in 2013, he served as an Associate Professor and Qiushi Young Scholar until 2022, when he was promoted to Professor. His work as Dean Assistant at the Institute of Translational Medicine and Deputy Director of the Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism showcases his leadership and contributions to the academic community. He also serves as a PI at the Cancer Institute of The Second Affiliated Hospital of Zhejiang University.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Wang’s research primarily revolves around cancer metabolism, cellular engineering, and biomedical innovations. His innovative research in translational medicine seeks to bridge laboratory research with practical clinical applications. Key areas of his research include:
    • Surface engineering for single-cell modification
    • Metabolism-related cancer research
    • Advancements in transvascular implantation devices

    Dr. Wang has also played a critical role as a panel judge for the National Natural Science Foundation of China and has been actively involved in several international research collaborations, contributing to a wide range of scientific publications.

🌍Impact and Influence

  • Dr. Wang’s impact extends beyond research, with significant contributions to education and mentorship. He has undertaken extensive teaching responsibilities, from undergraduate biology courses to graduate thesis guidance, impacting hundreds of students. His mentorship has produced many successful Ph.D. and master’s candidates who have gone on to establish themselves in academia and industry.As a journal reviewer for numerous prestigious scientific publications, including ACS Nano, Advanced Materials, and Biomaterials, Dr. Wang has helped shape the discourse in chemistry, biology, and biomedical engineering fields. His expertise is highly sought after by journals such as Chemical Science and Journal of Controlled Release.

🏅ACADEMIC CITES 

  • Dr. Wang Ben’s research is widely recognized within the academic community, reflected in his growing number of citations. His Google Scholar profile shows a robust citation record, underscoring the influence of his research in both cancer metabolism and biomedical engineering fields.

 📚LEGACY AND FUTURE CONTRIBUTIONS

  • Dr. Wang’s legacy in the field of cancer metabolism and transvascular implantation devices continues to grow. His future work promises to contribute further to cancer treatment, aiming to integrate innovative biomedical solutions into mainstream healthcare. His leadership roles and international collaborations highlight his dedication to driving forward impactful translational medical research.

📰PUBLICATIONS

  • Acid-base transformative HADLA micelles alleviate colitis by restoring adaptive immunity and gut microbiome
    • Authors: Cheng, W.; Zhou, X.; Jin, C.; Ji, F.; Wang, B.
    • Journal: Journal of Controlled Release, 2023, Volume 364, Pages 283–296.
  • Targeted glycan degradation potentiates cellular immunotherapy for solid tumors
    • Authors: Wu, J.; Wang, X.; Huang, Y.; Zhang, J.; Wang, B.
    • Journal: Proceedings of the National Academy of Sciences of the United States of America, 2023, Volume 120(38), Article e2300366120.
  •  A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch
    • Authors: Sun, Y.; He, Q.; Li, J.; Luo, H.; Luo, Y.
    • Journal: Cell Death and Disease, 2023, Volume 14(7), Article 463.
  •  Renal tubule-targeted dexrazoxane suppresses ferroptosis in acute kidney injury by inhibiting ACMSD
    • Authors: Zhang, Y.; Wu, J.; An, Q.; Wang, B.; Lin, W.
    • Journal: Nano Research, 2023, Volume 16(7), Pages 9701–9714.
  • Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine
    • Authors: Zhang, Q.; Wu, P.; Wu, J.; Wang, S.; Wang, B.
    • Journal: ACS Nano, 2023, Volume 17(8), Pages 7498–7510.